Dynavax Technologies Co. (NASDAQ:DVAX) Stake Lessened by Twinbeech Capital LP

Twinbeech Capital LP lowered its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 9.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,743 shares of the biopharmaceutical company’s stock after selling 6,540 shares during the period. Twinbeech Capital LP’s holdings in Dynavax Technologies were worth $801,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DVAX. Barclays PLC lifted its holdings in shares of Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after purchasing an additional 175,118 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of Dynavax Technologies in the fourth quarter valued at $137,000. Nisa Investment Advisors LLC lifted its holdings in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies in the fourth quarter valued at $990,000. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Dynavax Technologies by 4.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 162,726 shares of the biopharmaceutical company’s stock valued at $2,078,000 after purchasing an additional 6,712 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $9.90 on Thursday. Dynavax Technologies Co. has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The stock’s 50-day moving average is $11.56 and its two-hundred day moving average is $12.46. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.19 billion, a P/E ratio of 55.00 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. JMP Securities cut their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.